A 12-Month, multicenter, double-blind, randomized, parallel group study comparing 150 mg once-a-month risedronate [risedronic acid] and placebo using 3-dimensional micro MRI [magnetic resonance imaging].

Trial Profile

A 12-Month, multicenter, double-blind, randomized, parallel group study comparing 150 mg once-a-month risedronate [risedronic acid] and placebo using 3-dimensional micro MRI [magnetic resonance imaging].

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2010

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Bone resorption
  • Focus Therapeutic Use
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 31 Mar 2010 Warner Chilcott as trial sponsor, trial affiliate and additional lead trial centre added as reported by ClinicalTrials.gov.
    • 23 Dec 2009 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Actual patient number (13) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top